Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Medical Economics|November 28, 2015
Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemiaJohn Whalen, Ipek Stillman, Apoorva Ambavane, et al.
Clinical Therapeutics|June 6, 2006
Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: A series of retrospective analyses of data from 1998 through 2002Kathleen M Fox, Robert A Gerber Pharmd, Bjorn Bolinder, et al.
Cancer Investigation|November 17, 2025
Patient-Centered Real-World Evidence Framework for Oncology Product DevelopmentNenad Medic, Dina Filipenko, Monica Hadi, et al.
Pharmacoeconomics|August 16, 2005
Real-world trials to answer real-world questionsNick Freemantle, Lawrence Blonde, Bjorn Bolinder, et al.
American Journal of Clinical Oncology|September 24, 2015
Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United StatesVeena Shankaran, Jesse D Ortendahl, Anna G Purdum, et al.
Diabetes Technology & Therapeutics|June 1, 2006
Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) modelElvira Mueller, Stefanie Maxion-Bergemann, Dmitry Gultyaev, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 26, 2015
The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community SettingNicholas J Di Bella, Debajyoti Bhowmik, Menaka Bhor, et al.
MDM Policy & Practice|August 8, 2022
Estimating Productivity Loss from Breast and Non-Small-Cell Lung Cancer among Working-Age Patients and Unpaid Caregivers: A Survey Study Using the Multiplier MethodKevin Chiu, Joanna P MacEwan, Suepattra G May, et al.
Pageof 1